

HEALEY ALS Platform Trial

Weekly Q&A – Oct 20, 2022



Healey Center

Sean M. Healey & AMG Center
for ALS at Mass General



The AMG Foundation




Guest Speaker



Amanda Peltier, MD, MS

Platform Trial Site Investigator
Vanderbilt University Medical Center
Nashville, TN


VUMC and Allied Hospitals, TN



VUMC Neuromuscular Division Faculty



The Vanderbilt ALS Multidisciplinary Clinic




ALS at Vanderbilt

- We have a multidisciplinary clinic monthly which currently serves ~125 patients from Tennessee, Kentucky and Alabama.
- We are supported by MDA and ALSA.
- Our clinic includes 4 neuromuscular specialists, 2 neuromuscular NP, pulmonology (1 MD, 1 NP), respiratory therapy, social work, palliative care, speech therapy, physical therapy, occupational therapy, assistive technology, nutrition
- We have 2 full time research coordinators.
- We have 10 patients who have been randomized in Healey

Thank You!!

- Your participation makes it possible for advances in ALS.
- We could not do it without you!

The HEALEY ALS Platform Trial is a Perpetual Adaptive Trial



Enrollment Updates (as of Oct 20, 2022)

- **153** individuals have signed informed consent
- **112** individuals have been randomized within Regimen E


Thank You

This breakthrough trial would not be possible without your participation

Your **partnership** in research is what keeps us filled with passion, dedication, and the commitment to uncover new promising treatments for ALS

Every research participant, whether on the active drug or placebo, plays a critical role in making the hope of finding a cure for ALS a reality

51 Sites Currently Activated for Regimen E



(as of 10/20/22)

Sites in blue participated in previous regimens. Sites in green (underlined to the side) are new additions to the Platform Trial!

- Lehigh Valley Health Network
- Mass General Hospital
- University of Kansas
- University of Maryland
- California Pacific Medical Center
- Northwestern University
- Virginia Commonwealth University
- University of Nebraska
- Washington University
- Wake Forest University
- Hospital for Special Care
- Saint Alphonsus Regional
- University of Massachusetts
- Duke University
- Barrow Neurological Institute
- Georgetown University
- Texas Neurology
- Beth Israel Deaconess Medical Center
- SUNY Upstate
- Spectrum Health
- Henry Ford Hospital
- Essentia Health
- University of Southern California
- University of South Florida
- University of Colorado
- Providence Brain and Spine
- University of Minnesota
- Loma Linda University
- University of Iowa
- Swedish Medical Center
- Ohio State University
- University of Cincinnati
- Thomas Jefferson University
- UC San Francisco
- Mayo Rochester
- University of Washington
- Vanderbilt University
- UPMC
- Indiana University
- Augusta University
- University of Utah
- Holy Cross Hospital
- Penn State Hershey
- University of CA, Irvine
- Cedars Sinai Medical Center
- University of Pennsylvania
- Nova Southeastern University
- Johns Hopkins University
- Columbia University
- Stony Brook University
- Kaiser, Los Angeles

Site Map & Contacts:



<https://bit.ly/3g2NZr5>

Patient Navigation

Central resource for people living with ALS



Catherine Small

Phone: 833-425-8257 (HALT ALS)

E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar
registration:



<https://bit.ly/3r6Nd2L>

ALS Link sign-up:



<https://bit.ly/3o2Ds3m>

Upcoming Cancelations:

November 3rd- Webinar canceled due to annual research conference

November 24th- Webinar canceled for holiday, Happy Thanksgiving!



Allison Bulat

Weekly Recordings Available on Website

Webinar Recordings

Science & Mechanism of Action Series +

Weekly & Monthly Updates -

October 6, 2022: Weekly Q&A featuring discussion of Regimen C/CNM-Au8 results

Merit Cudkowicz, MD, MSc and Sabrina Paganoni, MD, PhD presented this week's updates on the HEALEY ALS Platform Trial and answered questions from the audience. We were joined by the co-lead investigators for Regimen C and representatives from Clene Nanomedicine, Inc. to discuss the trial results for CNM-Au8.

[Watch recording.](#)

September 29, 2022: Weekly Q&A featuring discussion of Regimen B/Verdiperstat results

Merit Cudkowicz, MD, MSc and Sabrina Paganoni, MD, PhD presented this week's updates on the HEALEY ALS Platform Trial and answered questions from the audience. We were joined by the co-lead investigators for Regimen B and representatives from Biohaven Pharmaceuticals to discuss the trial results for Verdiperstat.

[Watch recording.](#)

Visit the Website:



<https://bit.ly/3g4kzfv>